Abstract

Novo-Nordisk A/S will report quarterly results on May 6, 2026, Pre-Market, and consensus tracks a modest year-over-year revenue decline alongside resilient margins and nearly flat adjusted EPS, with most institutions maintaining a neutral stance.

Market Forecast

Consensus and company projections point to total revenue of 74.64 billion US dollars for the current quarter, a 4.40% year-over-year decrease, with EBIT at 34.40 billion US dollars (-6.57% year over year) and adjusted EPS at 6.13 (+0.41% year over year); margins are expected to remain robust relative to the last-reported 82.10% gross profit margin and 33.98% net profit margin. Diabetes and obesity care is projected to remain the core growth engine, supported by broad demand and expanding indications. The GLP-1 obesity portfolio is the most promising segment, anchored by a last-reported revenue base of 289.46 billion US dollars and strengthened by new data and label expansion opportunities.

Last Quarter Review

Novo-Nordisk A/S posted revenue of 79.14 billion US dollars, a 7.63% year-over-year decrease, with a gross profit margin of 82.10%, GAAP net profit attributable to the parent company of 26.89 billion US dollars, a net profit margin of 33.98%, and adjusted EPS of 6.04 (down 4.73% year over year). Net profit grew 34.41% quarter over quarter, reflecting operating leverage and mix benefits despite a softer year-over-year top line. The main business mix was led by diabetes and obesity care at 289.46 billion US dollars and rare disease at 19.61 billion US dollars, with segment-level year-over-year detail not disclosed.

Current Quarter Outlook

Main Business: Diabetes and Obesity Care

Diabetes and obesity care remains the center of Novo-Nordisk A/S’s revenue profile this quarter, with consensus modeling a modest contraction in total revenue but broadly resilient profitability. The last quarter’s margins (82.10% gross and 33.98% net) set a high bar, and the current quarter’s expectations imply continued pricing discipline, favorable mix from GLP-1 therapies, and cost control to protect EBIT, which is forecast at 34.40 billion US dollars. The company’s adjusted EPS profile is expected to edge higher by 0.41% year over year, indicating that consensus anticipates modestly tighter expense control and supportive mix even as reported revenue declines by 4.40% year over year.

Commercial momentum for the diabetes and obesity portfolio looks supported by expanding indications and the broadening of prescriber confidence around semaglutide-based therapies. Recent late-stage data in pediatric type 2 diabetes for oral semaglutide showed superiority versus placebo in lowering blood sugar measures with a well-tolerated safety profile, reinforcing clinicians’ comfort with the molecule class and opening a path to extend reach into younger patient cohorts. Operationally, supply continuity and logistics remain a watch item, but the quarter-on-quarter net profit improvement of 34.41% in the prior print suggests the company is executing well on manufacturing, channel fill, and cost management, positioning the franchise to absorb demand variability while sustaining margin quality.

The key to this quarter’s main business performance is balancing volume growth, prescription durability, and payer dynamics in the face of competitive intensity. While consensus expects a revenue decline year over year, the projected increase in adjusted EPS and the scale of last quarter’s margins indicate that Novo-Nordisk A/S can offset part of the top-line pressure through mix, pricing, and disciplined operating expenses. Execution on new patient starts, retention rates, and the cadence of label expansion should drive incremental revenue stability, while manufacturing yields and distribution agility remain critical to protecting EBIT against temporary demand fluctuations or inventory normalization.

Most Promising Business: GLP-1 Obesity Portfolio and Label Expansion

The GLP-1 obesity portfolio appears to be the most promising business this quarter, underpinned by strong demand fundamentals and supportive clinical updates. With a last-reported revenue base of 289.46 billion US dollars in diabetes and obesity care, the segment benefits from a large installed patient base and widening prescriber adoption, particularly where oral formulations improve accessibility or adherence. The latest readouts in pediatric type 2 diabetes for oral semaglutide—demonstrating superior glycemic control—underscore the potential for differentiated patient pathways and expanded population coverage, while ongoing work in additional indications may further extend addressable demand.

This quarter, investor attention centers on how semaglutide-based products can maintain trajectory in light of competitive entrants and payer reviews. The modest year-over-year revenue decline in the forecast is not inconsistent with normalizing growth rates following an extraordinary scaling period; however, the projected small year-over-year uplift in adjusted EPS highlights the expectation that pricing, cost efficiency, and product mix will preserve earnings quality even as total revenue normalizes. In practice, incremental volume growth from new cohorts, better adherence with oral options, and strategic allocation of manufacturing capacity are likely to be the near-term levers for the portfolio.

Progress on regulatory interactions, pediatric and adolescent use, and broader clinical endpoints will shape sentiment and the medium-term top-line opportunity. Any updates on patient conversion to oral formulations, prescriber uptake trends in primary care settings, and managed care prioritization will be pivotal for gauging run-rate sustainability. The GLP-1 obesity segment remains positioned to anchor margin performance due to its scale and pricing power, and consensus expectations imply that profitability can outpace revenue growth given operational efficiencies and the potential for a richer mix within the therapy class.

Stock Price Drivers This Quarter

The first stock price driver this quarter is the trajectory of GLP-1 demand, the cadence of new patient starts, and conversion dynamics from injectable to oral semaglutide, especially in cohorts where adherence or convenience alters utilization patterns. Investors will parse commentary on weekly new prescriptions, discontinuation rates, and refill behavior to triangulate near-term run-rate revenue, with any signs of stabilization or reacceleration likely to influence the price action. At the same time, clarity on supply sufficiency and manufacturing throughput will be critical because temporary constraints can affect channel inventory and reported growth.

The second driver is margins—specifically gross profit margin and EBIT discipline—given consensus expectation for revenue to contract year over year but adjusted EPS to edge higher. Management commentary on cost rationalization, procurement benefits, and efficiencies across production and distribution will be closely watched. A consistent or slightly increasing gross margin versus the last-reported 82.10% would validate that pricing and mix are holding, while EBIT containment near the 34.40 billion US dollars forecast would confirm that cost actions are offsetting top-line headwinds.

The third driver is the clinical and regulatory pipeline narrative within rare diseases and cardiometabolic indications, which can affect sentiment even if near-term revenue contribution is modest. Positive late-stage outcomes or regulatory designations can reset medium-term expectations on the company’s innovation cadence and diversify the earnings stream. Conversely, any material setbacks or delays could prompt temporary caution if investors extrapolate pipeline risk into valuation. Across these drivers, guidance and qualitative color on payer negotiations, label expansions, and regional uptake patterns will be scrutinized to refine expectations for the remainder of the year.

Analyst Opinions

The majority institutional stance is neutral, with most firms maintaining Hold ratings and price targets that imply balanced risk-reward through this reporting cycle. J.P. Morgan’s Richard Vosser reiterated a Hold with a DKK 250.00 target, framing expectations around disciplined execution and an earnings profile resilient to normalization in top-line growth. Barclays’ James Gordon also maintained a Hold, recently setting DKK 270.00 targets in one note and DKK 340.00 in another, indicating that while long-term innovation prospects are constructive, near-term valuation and revenue trajectory warrant caution.

Deutsche Bank’s Emmanuel Papadakis reaffirmed a Hold with DKK 275.00, reflecting views that this quarter’s setup is not a catalyst for a decisive re-rating without clearer evidence of sustained volume acceleration or an upside surprise on margins beyond consensus. Goldman Sachs’ James Quigley downgraded to Hold with DKK 260.00, pointing to a more balanced profile of risks and opportunities as revenue moderates and the company navigates competition and payer considerations. Morgan Stanley’s Thibault Boutherin upgraded to Hold with a 40.00 US dollars target, aligning with the neutral consensus that short-term outcomes are likely bounded by manageable top-line pressures and intact margin quality.

Within this neutral majority, analysts highlight several themes. First, consensus expects revenue to decrease by 4.40% year over year to 74.64 billion US dollars, indicating normalization after periods of rapid expansion; the focus shifts to operational excellence and margin durability rather than top-line acceleration. Second, adjusted EPS is forecast to rise by 0.41% year over year to 6.13, underscoring expectations for cost discipline and a supportive product mix to protect earnings even as revenue softens. Third, EBIT is projected at 34.40 billion US dollars, down 6.57% year over year, suggesting the Street anticipates continued investment and measured operating expenditure while retaining a high-margin structure.

Analysts also note that last quarter’s 82.10% gross margin and 33.98% net margin frame expectations for this print, with the prior quarter’s 34.41% quarter-on-quarter net profit increase demonstrating the company’s capacity to manage through demand variability and capitalize on mix improvements. The neutral stance reflects the view that, absent an outsized upside surprise on revenue or a step-change in margin, the report is unlikely to dramatically alter valuation in the immediate term. However, institutions are poised to reassess if management provides clearer visibility on sustained volume growth, expanded indications with near-term commercial impact, or tangible signs that manufacturing capacity can meaningfully elevate supply to absorb demand without compromising profitability.

Moreover, the neutral consensus incorporates competitive dynamics in obesity care and diabetes therapies, where innovation cycles and payer policies can influence trajectory over several quarters. Analysts expect Novo-Nordisk A/S to continue focusing on execution against clinical milestones and operational throughput, with investors monitoring pediatric and oral semaglutide progress, pipeline readouts, and regional uptake signals. In this context, the majority view counsels patience: the quarter is seen as a checkpoint on margin resilience and strategic focus rather than a decisive inflection in growth, and valuation is likely to respond most to incremental clarity on the pace and breadth of future expansion rather than this quarter’s headline numbers alone.